INTS (Intensity Therapeutics, Inc. Common stock) Stock Analysis - Politician Trades

Intensity Therapeutics, Inc. Common stock (INTS) is a publicly traded Healthcare sector company. As of May 21, 2026, INTS trades at $4.63 with a market cap of $12.38M and a P/E ratio of -0.54. INTS moved +0.87% today. Year to date, INTS is -53.23%; over the trailing twelve months it is -55.35%. Its 52-week range spans $4.50 to $100.00. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces INTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded INTS stock?

Rallies tracks politician and congressional stock disclosures for INTS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

INTS Key Metrics

Key financial metrics for INTS
MetricValue
Price$4.63
Market Cap$12.38M
P/E Ratio-0.54
EPS$-8.56
Dividend Yield0.00%
52-Week High$100.00
52-Week Low$4.50
Volume0
Avg Volume0
Revenue (TTM)$0
Net Income$-11.61M
Gross Margin0.00%

Latest INTS News

INTS Analyst Consensus

2 analysts cover INTS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.

Common questions about INTS

Which politicians traded INTS stock?
Rallies tracks politician and congressional stock disclosures for INTS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in INTS?
Yes. Rallies tracks politician and congressional stock disclosures for INTS, including reported purchases, sales, dates, owners, and trade amounts when available.
Is INTS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for INTS. It does not provide personalized investment advice.
INTS

INTS